JP2023515385A - アデノ随伴ウイルス用安定化剤及びこれを用いたアデノ随伴ウイルスの安定化方法 - Google Patents
アデノ随伴ウイルス用安定化剤及びこれを用いたアデノ随伴ウイルスの安定化方法 Download PDFInfo
- Publication number
- JP2023515385A JP2023515385A JP2022548843A JP2022548843A JP2023515385A JP 2023515385 A JP2023515385 A JP 2023515385A JP 2022548843 A JP2022548843 A JP 2022548843A JP 2022548843 A JP2022548843 A JP 2022548843A JP 2023515385 A JP2023515385 A JP 2023515385A
- Authority
- JP
- Japan
- Prior art keywords
- adeno
- associated virus
- aav
- surfactant
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 68
- 239000003381 stabilizer Substances 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 23
- 230000000087 stabilizing effect Effects 0.000 title abstract description 5
- 239000004094 surface-active agent Substances 0.000 claims abstract description 78
- 102000009027 Albumins Human genes 0.000 claims abstract description 43
- 108010088751 Albumins Proteins 0.000 claims abstract description 43
- 230000002776 aggregation Effects 0.000 claims abstract description 24
- 238000004220 aggregation Methods 0.000 claims abstract description 24
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 13
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical group OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 47
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 46
- 239000001263 FEMA 3042 Substances 0.000 claims description 46
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 46
- 229940033123 tannic acid Drugs 0.000 claims description 46
- 235000015523 tannic acid Nutrition 0.000 claims description 46
- 229920002258 tannic acid Polymers 0.000 claims description 46
- 239000000126 substance Substances 0.000 claims description 17
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 7
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 7
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 7
- 125000002091 cationic group Chemical group 0.000 claims description 5
- 125000000129 anionic group Chemical group 0.000 claims description 4
- 150000003943 catecholamines Chemical class 0.000 claims description 4
- 239000002245 particle Substances 0.000 abstract description 80
- 239000002105 nanoparticle Substances 0.000 abstract description 19
- 108090000623 proteins and genes Proteins 0.000 abstract description 18
- 241000700605 Viruses Species 0.000 abstract description 17
- 238000012546 transfer Methods 0.000 abstract description 9
- 238000001415 gene therapy Methods 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 238000012377 drug delivery Methods 0.000 abstract description 4
- 238000009877 rendering Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 76
- 239000013078 crystal Substances 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 26
- 238000002156 mixing Methods 0.000 description 26
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 24
- 229920000053 polysorbate 80 Polymers 0.000 description 24
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 10
- 229960003964 deoxycholic acid Drugs 0.000 description 9
- 239000002736 nonionic surfactant Substances 0.000 description 9
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 9
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 8
- 238000002296 dynamic light scattering Methods 0.000 description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
- 239000010931 gold Substances 0.000 description 8
- 229910052737 gold Inorganic materials 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 239000003945 anionic surfactant Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003093 cationic surfactant Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229920002113 octoxynol Polymers 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 239000002888 zwitterionic surfactant Substances 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 208000019061 glycogen storage disease due to GLUT2 deficiency Diseases 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 208000005189 Embolism Diseases 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- -1 alcohol sulfate ester Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960000800 cetrimonium bromide Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical group S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940117927 ethylene oxide Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium group Chemical group [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Abstract
Description
実施例1.実験材料及び実験方法
本発明の実施例で用いたタンニン酸(T0200)及び金ナノ粒子(900484)は、Sigma-Aldrich製から購入した。
本発明者らは、AAVを用いた遺伝子伝達体を製造する場合、AAVの凝集が起こる問題点を改善するために、界面活性剤を処理し、これによるAAV安定性の変化を確認しようとしたとともに、このために、当該技術分野で知られている様々な種類の界面活性剤を対象に効果を検証しようとした。より具体的には、それぞれのTween 80、Triton X、CHAPS、セトリモニウムブロミド(Cetrimonium bromide、CTAB)、及びデオキシコール酸ナトリウム(Sodium deoxycholate)が0.05%(w/w)(PBS、pH7.4)で存在する1×108genome/μl AAV溶液に0.5mMのタンニン酸溶液50μLを混合した後、約10分後に動的光散乱法(dynamic light scattering、DLS)によって平均粒子サイズを測定し、顕微鏡で血管閉塞現象をもたらす可能性のある結晶が形成されるか否かを観察した。この際、界面活性剤を処理していない条件としては、1×108genome/μl AAV溶液(PBS、pH7.4)50μLに0.5mMのタンニン酸溶液50μLを混合した後、上記と同様の方法で平均粒子サイズの測定及び顕微鏡観察を行った。
前記実施例2の結果より、界面活性剤を一緒に処理することにより、AAVとタンニン酸とを混合する場合、凝集して結晶が形成されることを抑制することができることを確認した。したがって、これに加えて、界面活性剤の好ましい濃度比率を確認するために、界面活性剤の濃度別粒子形成様相を分析した。
非イオン性界面活性剤であるTween 80がそれぞれ0.2%、0.05%、0.0125%、0.003%(w/w)(PBS、pH7.4)で存在する1×108genome/μl AAV溶液に0.5mMのタンニン酸溶液50μLを混合した後、約5分後に散乱度測定のために600nm波長帯のUV-Vis吸光度を測定し、顕微鏡で結晶形成有無を観察した。
両性イオン界面活性剤であるCHAPSがそれぞれ0.4%、0.1%、0.025%、0.006%(w/w)(PBS、pH7.4)で存在する1×108genome/μl AAV溶液に0.5mMのタンニン酸溶液50μLを混合した後、約5分後に、散乱度測定のために600nm波長帯のUV-Vis吸光度を測定し、顕微鏡で結晶形成有無を観察した。
カチオン界面活性剤であるCTABがそれぞれ0.4%、0.1%、0.025%、0.006%(w/w)(PBS、pH7.4)で存在する1×108genome/μl AAV溶液に0.5mMのタンニン酸溶液50μLを混ぜた後、約5分後に散乱度測定のために600nm波長帯のUV-Vis吸光度を測定し、顕微鏡で結晶形成有無を観察した。
アニオン界面活性剤であるデオキシコール酸ナトリウム(Sodium deoxycholate)がそれぞれ0.2%、0.05%、0.0125%、0.0003%(w/w)(PBS、pH7.4)で存在する1×108genome/μl AAV溶液に0.5mMのタンニン酸溶液50μLを混ぜた後、約5分後に、散乱度測定のために600nm波長帯のUV-Vis吸光度を測定し、顕微鏡で結晶形成有無を観察した。
マイクロ又はナノ粒子の形成は、外部環境の影響によって形成される様相が変わることができ、特にpH条件によって粒子形成の様相が変わることができる。したがって、本発明者らは、pH条件によるAAVの安定性の変化有無を検証しようとした。このために、pHが異なるそれぞれの異なる緩衝溶液(PBS pH7.4、クエン酸pH4.6、DDW pH3.0)を用いて、Tween 80及びCHAPSがそれぞれ0.05%(w/w)(PBS、pH7.4)で存在する1×108genome/μl AAV溶液を製造し、ここに0.5mMのタンニン酸溶液50μLを混合した後、約5分後に動的光散乱法によって平均粒子サイズを測定し、顕微鏡で結晶形粒子の形成有無を観察した。
AAV粒子は、混合後から注入に至る時間までそのサイズと形状を一定に維持しなければならない。したがって、混合後から注入までにかかる時間として推定される30分及び十分な時間である1日が経過した後まで粒子サイズが維持されるか否かを分析した。このために、Tween 80が0.01%(w/w)(PBS、pH7.4)で存在する1×108genome/μl AAV溶液に0.5mMのタンニン酸溶液50μLを混合した後、約5分後に、動的光散乱法を用いてそれぞれ0分(min)、20分、1日(day)目の平均粒子サイズを測定し、初期値に比べて粒子のサイズ増加を比較した。
本発明者らは、ポリフェノールと界面活性剤との結合を用いた粒子形成の際に追加の添加物を処理することにより、粒子のサイズをさらに縮小しようとした。このために、前記添加物としてアルブミンを選定してこれによる効果を検証した。
アルブミンが様々な濃度10%、1%、0.1%、0.01%(w/w)(PBS、pH7.4)で存在する1×108genome/μl AAV溶液に0.5mMのタンニン酸溶液50μLを混合した後、約10分後に、動的光散乱法によって平均粒子サイズを測定し、顕微鏡で粒子形成有無を観察した。
次に、アルブミンが各界面活性剤を用いて既に形成された粒子のサイズをさらに縮小することができるかを調べるために、Tween 80が0.01%(w/w)、CHAPS及びCTABそれぞれが0.05%(w/w)(PBS、pH7.4)で存在する1×108genome/μl AAV溶液に0.5mMのタンニン酸溶液50μLを混合し、約5分後に10%(w/w)アルブミン溶液50μLを混合した後、動的光散乱法によって平均粒子サイズを測定し、顕微鏡で観察した。
本発明者らは、界面活性剤とタンニン酸との結合効果を用いて、AAVの他に遺伝子伝達体として利用できる無機ナノ粒子である金ナノ粒子の安定性も維持されるかを調べるために、次の実験を行った。具体的には、Tween 80、CHAPS及びCTABがそれぞれ0.05%(w/w)(PBS、pH7.4)で存在する450nm吸光度0.1AU濃度の金ナノ粒子溶液50μLに0.5mMのタンニン酸溶液50μLを混合した後、約5分後に動的光散乱法によって平均粒子サイズを測定し、顕微鏡で観察した。また、対照群として界面活性剤が添加されていない同一の条件で実験を行った。
Claims (12)
- 界面活性剤又はアルブミンを含む、アデノ随伴ウイルス(Adeno-Associated Virus、AAV)用安定化剤。
- 前記界面活性剤は5~20の親水性-親油性バランス(Hydrophile-Lipophile Balance、HLB)値を有することを特徴とする、請求項1に記載の安定化剤。
- 前記界面活性剤は、アニオン性(Anionic)、カチオン性(Cationic)、非イオン性(Nonionic)及び両性イオン型(Zwitterionic)よりなる群から選択されることを特徴とする、請求項2に記載の安定化剤。
- 前記安定化剤は前記アデノ随伴ウイルスの凝集を阻害することを特徴とする、請求項1に記載の安定化剤。
- 前記アデノ随伴ウイルスはポリフェノール系物質で表面改質されていることを特徴とする、請求項1に記載の安定化剤。
- 前記ポリフェノール系物質はタンニン酸(Tannic acid)、カテコールアミン(Catecholamine)、又は没食子酸エピガロカテキン(Epigallocatechin gallate、EGCG)であることを特徴とする、請求項5に記載の安定化剤。
- 前記アルブミンは10~0.01%(w/w)の濃度で含まれることを特徴とする、請求項1に記載の安定化剤。
- アデノ随伴ウイルス(Adeno-Associated Virus、AAV)及び安定化剤を含み、前記安定化剤は界面活性剤又はアルブミンを含有することを特徴とする、アデノ随伴ウイルス液状製剤。
- 前記液状製剤はpH3.0~8.0に維持されることを特徴とする、請求項8に記載の液状製剤。
- アデノ随伴ウイルス(Adeno-Assaciated Virus、AAV)に安定化剤を処理する段階を含み、前記安定化剤は界面活性剤又はアルブミンを含むことを特徴とする、安定性が増進したアデノ随伴ウイルスの製造方法。
- 前記アデノ随伴ウイルスはポリフェノール系物質で表面改質されていることを特徴とする、請求項10に記載の製造方法。
- 前記ポリフェノール系物質はタンニン酸(Tannic acid)、カテコールアミン(Catecholamine)、又は没食子酸エピガロカテキン(Epigallocatechin gallate、EGCG)であることを特徴とする、請求項11に記載の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200015744A KR102167829B1 (ko) | 2020-02-10 | 2020-02-10 | 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법 |
KR10-2020-0015744 | 2020-02-10 | ||
PCT/KR2020/016512 WO2021162211A1 (ko) | 2020-02-10 | 2020-11-20 | 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023515385A true JP2023515385A (ja) | 2023-04-13 |
Family
ID=73025354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022548843A Pending JP2023515385A (ja) | 2020-02-10 | 2020-11-20 | アデノ随伴ウイルス用安定化剤及びこれを用いたアデノ随伴ウイルスの安定化方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220372498A1 (ja) |
EP (1) | EP4104866A4 (ja) |
JP (1) | JP2023515385A (ja) |
KR (1) | KR102167829B1 (ja) |
CN (1) | CN115103692A (ja) |
AU (1) | AU2020428501A1 (ja) |
CA (1) | CA3167351A1 (ja) |
WO (1) | WO2021162211A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102167829B1 (ko) * | 2020-02-10 | 2020-10-20 | 주식회사 이노테라피 | 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법 |
AU2022271280A1 (en) * | 2021-05-07 | 2023-11-09 | Board Of Regents, The University Of Texas System | Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules |
JP2023141423A (ja) * | 2022-03-24 | 2023-10-05 | 国立大学法人 東京大学 | ウイルスの精製方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108525A1 (en) * | 1998-12-03 | 2003-06-12 | Sista Hema S. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
US20040101964A1 (en) * | 2000-05-10 | 2004-05-27 | Shigemitsu Takashima | Method of preparing virus vector |
JP2005538939A (ja) * | 2002-04-11 | 2005-12-22 | メディミューン・ヴァクシンズ・インコーポレーテッド | 凍結乾燥フォームによる生物活性材料の保存 |
JP2019505183A (ja) * | 2015-12-14 | 2019-02-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | クリグラー・ナジャー症候群の処置のための組成物 |
KR20190045174A (ko) * | 2016-07-21 | 2019-05-02 | 스파크 테라퓨틱스, 인코포레이티드 | 재조합 아데노신 관련 바이러스(rAAV) 벡터를 고수율로 생산하기 위한 확장 가능한 고회수 방법 및 이에 의해 생산된 재조합 아데노-관련 바이러스(rAAV) 벡터 |
KR20190111253A (ko) * | 2018-03-22 | 2019-10-02 | 한국화학연구원 | 탄닌산을 포함하는 심장 표적화제 |
JP2019530463A (ja) * | 2016-10-13 | 2019-10-24 | ユニバーシティ オブ マサチューセッツ | Aavカプシド設計 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3290513B1 (en) * | 2004-06-01 | 2022-09-07 | Genzyme Corporation | Compositions and methods to prevent aav vector aggregation |
CN101018858A (zh) * | 2004-06-01 | 2007-08-15 | 建新公司 | 防止aav载体聚集的组合物和方法 |
CN102205132B (zh) * | 2011-05-12 | 2014-04-02 | 华侨大学 | 一种以重组腺相关病毒为载体的基因治疗药物的制剂处方 |
AU2016326602A1 (en) * | 2015-09-24 | 2018-03-29 | Biomarin Pharmaceutical Inc. | Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same |
KR102167829B1 (ko) * | 2020-02-10 | 2020-10-20 | 주식회사 이노테라피 | 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법 |
-
2020
- 2020-02-10 KR KR1020200015744A patent/KR102167829B1/ko active IP Right Grant
- 2020-11-20 CN CN202080096092.1A patent/CN115103692A/zh not_active Withdrawn
- 2020-11-20 CA CA3167351A patent/CA3167351A1/en active Pending
- 2020-11-20 EP EP20918323.5A patent/EP4104866A4/en active Pending
- 2020-11-20 AU AU2020428501A patent/AU2020428501A1/en active Pending
- 2020-11-20 JP JP2022548843A patent/JP2023515385A/ja active Pending
- 2020-11-20 WO PCT/KR2020/016512 patent/WO2021162211A1/ko unknown
-
2022
- 2022-08-08 US US17/882,772 patent/US20220372498A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108525A1 (en) * | 1998-12-03 | 2003-06-12 | Sista Hema S. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
US20040101964A1 (en) * | 2000-05-10 | 2004-05-27 | Shigemitsu Takashima | Method of preparing virus vector |
JP2005538939A (ja) * | 2002-04-11 | 2005-12-22 | メディミューン・ヴァクシンズ・インコーポレーテッド | 凍結乾燥フォームによる生物活性材料の保存 |
JP2019505183A (ja) * | 2015-12-14 | 2019-02-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | クリグラー・ナジャー症候群の処置のための組成物 |
KR20190045174A (ko) * | 2016-07-21 | 2019-05-02 | 스파크 테라퓨틱스, 인코포레이티드 | 재조합 아데노신 관련 바이러스(rAAV) 벡터를 고수율로 생산하기 위한 확장 가능한 고회수 방법 및 이에 의해 생산된 재조합 아데노-관련 바이러스(rAAV) 벡터 |
JP2019530463A (ja) * | 2016-10-13 | 2019-10-24 | ユニバーシティ オブ マサチューセッツ | Aavカプシド設計 |
KR20190111253A (ko) * | 2018-03-22 | 2019-10-02 | 한국화학연구원 | 탄닌산을 포함하는 심장 표적화제 |
Also Published As
Publication number | Publication date |
---|---|
CN115103692A (zh) | 2022-09-23 |
AU2020428501A1 (en) | 2022-09-01 |
EP4104866A4 (en) | 2024-04-10 |
EP4104866A1 (en) | 2022-12-21 |
KR102167829B1 (ko) | 2020-10-20 |
WO2021162211A1 (ko) | 2021-08-19 |
US20220372498A1 (en) | 2022-11-24 |
CA3167351A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023515385A (ja) | アデノ随伴ウイルス用安定化剤及びこれを用いたアデノ随伴ウイルスの安定化方法 | |
JP6941632B2 (ja) | Cnsターゲティングaavベクターおよびその使用方法 | |
ES2386549T3 (es) | Composición para inhibir la expresión de un gen diana | |
GB2596224A (en) | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids | |
EP3796893A1 (en) | Delivery of dna | |
Baran-Rachwalska et al. | Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles | |
JP2022518504A (ja) | 閉端dna(cedna)ならびに遺伝子療法または核酸療法に関連する免疫応答を低減させる方法における使用 | |
CN113677332B (zh) | 包含硅纳米颗粒的递送系统 | |
JP2015526490A (ja) | 干渉rnaの内在性メカニズムを調節することができる核酸配列を送達するための製剤 | |
US20230159938A1 (en) | Vlp for the treatment of a lysosomal storage disease | |
Bisazza et al. | The in vitro characterization of dextran-based nanobubbles as possible DNA transfection agents | |
Botto et al. | Cationic solid lipid nanoparticles as non viral vectors for the inhibition of hepatocellular carcinoma growth by RNA interference | |
JP2018531046A6 (ja) | 核酸ベースのtia−1阻害剤 | |
Louboutin et al. | Protecting neurons from HIV-1 gp120-induced oxidant stress using both localized intracerebral and generalized intraventricular administration of antioxidant enzymes delivered by SV40-derived vectors | |
Supe et al. | Liposome-polyethylenimine complexes for the effective delivery of HuR siRNA in the treatment of diabetic retinopathy | |
JP2023513302A (ja) | 治療的に活性な作用物質を内皮へと送達するための脂質組成物およびその使用 | |
Su et al. | MicroRNA-195 liposomes for therapy of Alzheimer's disease | |
EP3670652A1 (en) | Vlp for the treatment of a lysosomal storage disease | |
JP2024509844A (ja) | プラスミノーゲンを調節するための方法および組成物 | |
Ahmed Mashal | Design, elaboration, characterization and evaluation of niosome formulations for gene delivery to retina and brain | |
CN117897143A (zh) | Apoe和apob修饰的脂质纳米颗粒组合物及其用途 | |
CN117582417A (zh) | 药物-脂质颗粒及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220810 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230814 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20231113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240122 |